# 关于Andrew Hider 2025年7月7日，百特 Baxter International 宣 布 任命Andrew Hider为新任总裁兼首席执行官（CEO），并 加入公司董事会 ，任职将于不迟于2025年9月3日生效，具体时间取决于其当前工作交接的完成情况。此前担 任临时CEO的 Brent Shafer 将在Hider上任后转为独立董事会主席。 Hider在工业自动化和生命科学领域拥有超过25年的跨行业经验，以下是他的主要职业履历： Hider的领导风格以客户为中心，注重运营效率和股东价值，同时保持对质量和创新的关注。 高管评价 Baxter的 临时CEO Brent Shafer 表示："Hider是一位杰出的领导者，拥有卓越的运营能力、严谨的执行力 和创新精神。我们非常高兴他将成为百特（Baxter）的下一任首席执行官。Hider在全球多元化企业的领导经 验凸显了他管理复杂运营和为股东创造价值的能力，同时始终专注于质量和以客户为中心的重要使命。我们相 信他是带领百特迈向新篇章的合适人选。" # 公司近况 Baxter近年来经历了显著的战略转型，以下是其最新动态和战略规划： 业务重组与剥离 ...

Core Viewpoint - Boston Scientific (BSX) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1][6]. Earnings Performance - The company has a solid track record of surpassing earnings estimates, with an average surprise of 9.82% over the last two quarters [2]. - In the last reported quarter, Boston Scientific achieved earnings of $0.75 per share, exceeding the Zacks Consensus Estimate of $0.67 per share by 11.94% [3]. - For the previous quarter, the company reported earnings of $0.70 per share against an expectation of $0.65 per share, resulting in a surprise of 7.69% [3]. Earnings Estimates and Predictions - Recent estimates for Boston Scientific have been trending upward, indicating positive sentiment among analysts [6]. - The Zacks Earnings ESP for the company is currently +0.88%, suggesting increased bullishness regarding its near-term earnings potential [9]. - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) indicates a strong likelihood of another earnings beat [9]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [7]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [8].

A month has gone by since the last earnings report for Agilent Technologies (A) . Shares have added about 5.4% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Agilent due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns ...

Brainsway Ltd. Sponsored ADR (BWAY) shares rallied 5.3% in the last trading session to close at $11.49. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.7% gain over the past four weeks. The sharp upsurge in BWAY shares can be attributed to positive market sentiment surrounding the recent clinical trial results for BrainsWay's accelerated Deep TMS therapy in treating Major Depressive Disorder (MDD). The mult ...

6月17日，记者从自治区卫生健康委召开的新闻发布会获悉，按照今年商务部、国家卫生健康委等 12部门印发的《促进健康消费专项行动方案》的要求，广西相关部门多措并举，有效促进健康消费。 同时，广西支持中医药特色服务出口基地建设，推进中药类产品出口贸易。开展国家中医药服务出 口基地建设，连续3年从中央外经贸专项资金中每年给予基地100万资金，支持有条件的中医药企业"走 出去"，开展中医药国际科技合作、国际交流等，促进广西中药类商品开拓国际市场。2025年1—4月广 西出口中药材数量5386.5吨，同比增长19.4%，出口金额1.26亿元。广西进口中药材数量1.24万吨，同比 增长555.6%，进口金额约4032.3万元。 下一步，广西将引导"互联网+药品流通"发展，支持药品零售流通企业与网络平台加强合作，打 造"有医生的24小时药店"；促进医疗消费券与惠民政策落地，联动药品零售流通企业推出保健养生类等 系列满减优惠活动，持续培育和发展健康消费领域新质生产力，提升健康商品和服务供给质量，更好满 足人民美好生活需要。（关海芳 张振广） 在促进医疗消费方面，广西将适老化产品列入以旧换新补贴范围，促进适老化医疗产品消费。自 ...

Company Performance - High Tide Inc. reported a quarterly loss of $0.03 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.02, marking an earnings surprise of -50% [1] - The company posted revenues of $96.94 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 0.22% and showing an increase from year-ago revenues of $91.6 million [2] - Over the last four quarters, High Tide has surpassed consensus revenue estimates four times, but has only exceeded consensus EPS estimates once [2] Stock Performance - High Tide shares have declined approximately 26.2% since the beginning of the year, contrasting with the S&P 500's gain of 1.6% [3] - The current Zacks Rank for High Tide is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $102.27 million, and for the current fiscal year, it is -$0.07 on revenues of $404.52 million [7] - The estimate revisions trend for High Tide is mixed, and changes in estimates for the coming quarters and current fiscal year are anticipated following the recent earnings report [6][7] Industry Context - High Tide operates within the Zacks Medical - Products industry, which is currently ranked in the bottom 37% of over 250 Zacks industries [8] - The performance of stocks in this industry can be significantly influenced by the overall industry outlook, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

A month has gone by since the last earnings report for Perrigo (PRGO) . Shares have lost about 3.1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Perrigo due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, fresh ...

It has been about a month since the last earnings report for Zimmer Biomet (ZBH) . Shares have lost about 0.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Zimmer due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turn ...

Core Viewpoint - Boston Scientific shares have increased by approximately 3.3% over the past month, underperforming the S&P 500 index [1] Group 1: Earnings and Estimates - Estimates for Boston Scientific have trended upward in the past month, indicating positive sentiment among analysts [2] - The most recent earnings report highlighted important drivers for the stock's performance [1] Group 2: VGM Scores - Boston Scientific has a Growth Score of B, a Momentum Score of C, and a Value Score of D, placing it in the bottom 40% for the value investment strategy [3] - The aggregate VGM Score for Boston Scientific is C, which is relevant for investors not focused on a single strategy [3] Group 3: Outlook - The upward trend in estimates suggests a promising outlook for Boston Scientific, with a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [4] Group 4: Industry Performance - Boston Scientific is part of the Zacks Medical - Products industry, where Abbott has gained 1.6% over the past month [5] - Abbott reported revenues of $10.36 billion for the last quarter, reflecting a year-over-year increase of 4%, with EPS rising from $0.98 to $1.09 [5] - For the current quarter, Abbott is expected to post earnings of $1.25 per share, representing a 9.7% increase from the previous year [6]

Sanara MedTech Inc. (SMTI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -32.26%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced a loss of $0.18, delivering a surprise of 5.26%.Over the last four quarters, the company has surp ...